201 related articles for article (PubMed ID: 16580615)
1. Diagnosis and management of kidney involvement in Fabry disease.
Warnock DG; West ML
Adv Chronic Kidney Dis; 2006 Apr; 13(2):138-47. PubMed ID: 16580615
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease: diagnosis and management, with emphasis on the renal manifestations.
Warnock DG
Curr Opin Nephrol Hypertens; 2005 Mar; 14(2):87-95. PubMed ID: 15687833
[TBL] [Abstract][Full Text] [Related]
3. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
[TBL] [Abstract][Full Text] [Related]
4. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
5. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
Tahir H; Jackson LL; Warnock DG
J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
[TBL] [Abstract][Full Text] [Related]
6. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy and renal function in 201 patients with Fabry disease.
Schwarting A; Dehout F; Feriozzi S; Beck M; Mehta A; Sunder-Plassmann G;
Clin Nephrol; 2006 Aug; 66(2):77-84. PubMed ID: 16939062
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease: is there a role for enzyme replacement therapy?
Mehta AB
J Intern Med; 2013 Oct; 274(4):329-30. PubMed ID: 23662843
[No Abstract] [Full Text] [Related]
9. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
10. [Neurological manifestations of Fabry disease].
Mendióroz M; Fernández-Cadenas I; Montaner J
Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
[TBL] [Abstract][Full Text] [Related]
11. Fabry disease: kidney involvement and enzyme replacement therapy.
Siamopoulos KC
Kidney Int; 2004 Feb; 65(2):744-53. PubMed ID: 14717955
[No Abstract] [Full Text] [Related]
12. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
[TBL] [Abstract][Full Text] [Related]
13. [Results of enzyme replacement therapy in Fabry disease nephropathy].
Dussol B
Presse Med; 2007 Mar; 36 Spec No 1():1S43-7. PubMed ID: 17546767
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Talbot AS; Lewis NT; Nicholls KM
Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
[TBL] [Abstract][Full Text] [Related]
15. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
16. [Fatal outcome of a patient with Fabry disease in enzymatic treatment].
Moyano MJ; del Toro N; Amor J; Milán JA
Nefrologia; 2005; 25(2):207-8. PubMed ID: 15912661
[No Abstract] [Full Text] [Related]
17. Kidney transplantation in patients with Fabry disease.
Cybulla M; Walter KN; Schwarting A; Divito R; Feriozzi S; Sunder-Plassmann G;
Transpl Int; 2009 Apr; 22(4):475-81. PubMed ID: 19207191
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
Warnock DG
J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
[No Abstract] [Full Text] [Related]
19. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
20. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
